VEGFA and hepatocellular carcinoma: This trial enrolled 501 patients with advanced HCC who had not previously received systemic treatment, two-thirds of whom received atezolizumab (anti-PD-L1 blockade) plus bevacizumab (VEGF monoclonal antibody), while the others received sorafenib monotherapy.